Arran Babbs

I oversee day-to-day operations at CCVTM as part of the senior leadership team, ensuring we have the resources and capacity to run and deliver Phase I and Phase II clinical trials of candidate vaccines targeting tuberculosis, malaria, hepatitis C virus, HIV, Ebola, influenza, and emerging or outbreak pathogens. I also serve as the Small Research Facility Lead for Jenner Vaccine Trials.

At the Jenner Institute, our Phase I vaccine trials focus on assessing safety and immunogenicity in healthy volunteers, while Phase II studies evaluate vaccine efficacy. Our Phase III COVID-19 and malaria vaccine trials have contributed to supporting licensing applications.

The Jenner Vaccine Trials Team is part of the Oxford Collaborative Clinical Trials Unit (OxCCTU) which includes the Oxford Vaccine Group, Primary Care, and the Oxford Respiratory Trials Team.

Before joining the Jenner Institute, I managed a large portfolio of Phase II–IV clinical trials across a broad range of liver and inflammatory bowel diseases in Experimental Medicine. Prior to this I spent 16 years working in Professor Dame Kay Davies’ laboratory, researching viral-vector delivery of small RNAs to induce exon skipping and conducting in-vivo studies of small-molecule therapies for Duchenne Muscular Dystrophy.